Why internal scars won't stop growing

July 12, 2018

CHICAGO --- Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis -- the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.

A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.

Fibrosis - a progressive scarring and hardening of internal organs - is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.

In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor - the antennae on the cell -- to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.

Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.

"Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it," said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.

The paper will be published July 12 in the Journal of Clinical Investigation Insight.

"The leading cause of liver failure in western world is obesity and that's because of liver fibrosis," Varga said. "In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse."

Most fibrotic disease likely begins as normal repair of an injury, scientists said. "But if the immune system produces too much of an initial scar, it can't go back to normal," Varga said. "You have an unhealed scar that keeps growing and can wipe out the entire organ."

Not everyone's fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.

"There is an emerging direction for treating fibrosis with precision medicine," said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. "Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That's where precision medicine becomes really critical."

"The results of this study are encouraging," Varga said. "We are not saying this compound is ready to be a drug. It's an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step."

Varga has spent more than a decade researching the cause and treatment of scleroderma, a type of fibrosis that simultaneously affects multiple organs. He directs the Northwestern Scleroderma Program, a clinical and research effort that follows 1,500 patients with scleroderma.
-end-
This work was supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR42309), National Institute of General Medicine (GM101279), of the National Institutes of Health, and the Scleroderma Foundation.

Northwestern University

Related Scleroderma Articles from Brightsurf:

Novel educational program puts a human face on biomedical research
The goal of translational research is to speed research breakthroughs into clinical practice.

Higher estrogen levels linked to more severe disease in scleroderma
Scleroderma is a connective tissue disease that hardens the skin and scars the organs.

New regulator of immune responses discovered
Scientists have identified a new internal regulator which helps control the body's response to fight infection.

Inhibiting cancer-causing protein could prevent scleroderma fibrosis
Examining the autoimmune disease at the molecular level led researchers to a specific molecule that could be contributing to the disease progression in patients.

Potential therapeutic target for lung fibrosis identified
No current treatments reverse or stop lung fibrosis -- scarring of the lung that makes it difficult to breathe.

Regulatory and effector B cells control scleroderma
A Japan-based research team led by Kanazawa University have found reciprocal regulation of B cells on bleomycin-induced scleroderma model.

Why internal scars won't stop growing
A study has newly identified an immune trigger of some fibrotic diseases and an experimental compound to treat it.

New treatment lenebasum shows promise for diffuse cutaneous systemic sclerosis (dcSSc)
The results of an open label extension of a phase II study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that lenabasum continues to have acceptable safety and tolerability in diffuse cutaneous systemic sclerosis (dcSSc) with no severe or serious adverse events (AE).

Uncovering a mechanism causing chronic graft-vs-host disease after bone marrow transplant
MicroRNA-17-92 is required for the T-cell and B-cell pathogenicity that drives chronic graft-versus-host disease (cGVHD) after allogeneic bone marrow transplant (BMT), report investigators at The Medical University of South Carolina in an article prepublished online March 12, 2018 by Blood.

LJI researchers discover key driver of atopic dermatitis
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction.

Read More: Scleroderma News and Scleroderma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.